Alternate site health provider Option Care Health (NASDAQ: OPCH) will be reporting results this Thursday before the bell. Here’s what you need to know.
Option Care Health met analysts’ revenue expectations last quarter, reporting revenues of $1.47 billion, up 8.8% year on year. It was a slower quarter for the company, with full-year revenue guidance slightly missing analysts’ expectations and EPS in line with analysts’ estimates.
Is Option Care Health a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Option Care Health’s revenue to grow 4.7% year on year, slowing from the 16.3% increase it recorded in the same quarter last year.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Option Care Health has a history of exceeding Wall Street’s expectations.
Looking at Option Care Health’s peers in the healthcare providers & services segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Chemed delivered year-on-year revenue growth of 1.6%, beating analysts’ expectations by 1.2%, and Elevance Health reported revenues up 1.5%, topping estimates by 2.4%. Chemed traded up 10% following the results while Elevance Health was also up 5.5%.
Read our full analysis of Chemed’s results here and Elevance Health’s results here.
There has been positive sentiment among investors in the healthcare providers & services segment, with share prices up 10.8% on average over the last month. Option Care Health is up 3% during the same time and is heading into earnings with an average analyst price target of $40.09 (compared to the current share price of $27.80).
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
